"Phylogica’s lead first generation CPP has out-performed a competitor CPP known as the ‘zebra’ peptide in vivo in a model of melanoma (cancer) – see Figure 1 below."
Also note, that this is only Phylogica's first in vivo competitive read-out of its CPP technology in relation to their peptide vaccine program.
So far they're ticking all the right boxes. How so? Look what was highlighted in the announcement above.
"The advantages of our CPP platform have been well described in vitro and this outcomedemonstrates that those advantages do translate from better outcomes in the test tube tobetter outcomes in a living organism."
The quality of Phylogica's CPP in this model is different and so to is the improved cytoplasmic endosomal escape activity and that's what's driving the key outcome, i.e., survival.
Tony
PYC Price at posting:
2.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)